Our immunohistochemistry experiments demonstrated that the mu-opioid receptor co-localized with the dopamine D1 receptor in neurons of the cortex and caudate nucleus. On the basis of this physiological data we further investigated whether these two G protein coupled receptors formed hetero-oligomers in living cells. To demonstrate hetero-oligomerization we used a novel strategy, the method used harnessed the physiological cellular mechanism for transport of proteins to the nucleus. The nuclear translocation pathway was adapted for the visualization of mu-opioid hetero-oligomers with the dopamine D1 receptor. The receptor hetero-oligomer complex formed resulted in a significantly enhanced surface expression of mu-opioid receptor. This hetero-oligomer formation involved the interaction of mu-opioid receptor with the dopamine D1 receptor carboxyl tail, since a dopamine D1 receptor substituted with the carboxyl of the dopamine D5 receptor failed to increase surface expression of mu-opioid receptor.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejphar.2007.11.060 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unraveling the Molecular Architecture of Mosquito D1-Like Dopamine Receptors: Insights Into Ligand Binding and Structural Dynamics for Insecticide Development.
Proteins
January 2025
Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai, India.
Vector-borne diseases pose a severe threat to human life, contributing significantly to global mortality. Understanding the structure-function relationship of the vector proteins is pivotal for effective insecticide development due to their involvement in drug resistance and disease transmission. This study reports the structural and dynamic features of D1-like dopamine receptors (DARs) in disease-causing mosquito species, such as Aedes aegypti, Culex quinquefasciatus, Anopheles gambiae, and Anopheles stephensi.
View Article and Find Full Text PDF1-Methylxanthine enhances memory and neurotransmitter levels.
PLoS One
January 2025
Radiant Research Services Pvt. Ltd., Bangalore, India.
1-Methylxanthine (1-MX) is the major metabolite of caffeine and paraxanthine and might contribute to their activity. 1-MX is an adenosine receptor antagonist and increases the release and survivability of neurotransmitters; however, no study has addressed the potential physiological effects of 1-MX ingestion. The aim of this study was to compare the effect of 1-MX on memory and related biomarkers in rats compared to control.
View Article and Find Full Text PDFXanomeline-trospium (Cobenfy) for Schizophrenia: A Review of the Literature.
Clin Psychopharmacol Neurosci
February 2025
Department of Pharmacy Practice, Campbell University College of Pharmacy and Health Sciences, Buies Creek, NC, USA.
Schizophrenia is a chronic and severe mental illness associated with substantial morbidity and mortality. Antipsychotics primarily rely on direct dopamine blockade, leading to potential life-interfering adverse events. The purpose of this review is to describe the safety and efficacy of xanomeline-trospium (Cobenfy), a Food and Drug Administration approved treatment for schizophrenia in adults.
View Article and Find Full Text PDFWeight loss therapy and addiction: increased risk after bariatric surgery but reduced risk with GLP-1 receptor agonists.
Diabetes Metab
January 2025
Division of Diabetes, Nutrition and Metabolic Disorders, CHU Liège, Liège, Belgium; Division of Clinical Pharmacology, Centre for Interdisciplinary Research on Medicines (CIRM), Liège University, Liège, Belgium. Electronic address:
Background: Obesity is an increasing public health problem because of its high prevalence and associated morbidity and mortality. Two weight-loss strategies are currently used, either bariatric surgery or pharmacological therapy with glucagon-like peptide-1 receptor agonists (GLP-1RAs). Preclinical studies in rodents suggested an increased risk of additive disorders after bariatric surgery contrasting with a reduced risk with GLP-1RAs.
View Article and Find Full Text PDFPatent review of novel compounds targeting opioid use disorder (2018-2024).
Expert Opin Ther Pat
January 2025
Department of Pharmaceutical and Biomedical Sciences, Rudolph H. Raabe College of Pharmacy, Ohio Northern University, Ada, OH, USA.
Introduction: Opioids have served as a cornerstone in pain management for decades. However, the emergence of increasingly potent synthetic analogs brings forth a range of side effects, including respiratory depression, tolerance, dependence, constipation, and, more importantly, the development of severe and debilitating opioid use disorder (OUD). Search for therapeutics to mitigate OUD has been challenging and this has called for novel approaches that include design of small molecules targeting neuronal circuits involved in addiction (opioid, dopamine, serotonin, norepinephrine, and glutamate receptors, etc.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!